This is a routine equity plan replenishment for a pre-revenue biotech needing to retain talent. The vote is expected to pass with management's recommendation. No immediate price catalyst. Monitor next quarterly filing for clinical pipeline updates and cash runway — those are the primary drivers for ACRV at this stage.
Price Chart
Executive Summary
Acrivon Therapeutics filed a DEFA14A supplementing its definitive proxy for the June 17, 2026 Annual Meeting, adding a new Proposal 3 to amend and restate the 2022 Equity Incentive Plan. The amendment seeks to increase the share reserve by 3,000,000 shares (from 622,667 remaining to 3,622,667 available), modify the evergreen provision to use fully diluted shares including pre-funded warrants, and make conforming changes. The CEO and board unanimously recommend a FOR vote on all proposals. This is a routine compensation-related equity plan amendment aimed at preserving the company's ability to attract and retain talent; no financial results, M&A, or activist activity are involved.
Key Financial Metrics
Key Facts
- Annual Meeting scheduled for June 17, 2026; record date April 23, 2026
- New Proposal 3 requests approval to increase authorized shares under the 2022 Equity Incentive Plan by 3,000,000 shares (total available would become 3,622,667)
- As of May 18, 2026, only 622,667 shares remained for future issuance under the existing plan
- As of May 18, 2026, there were 7,760,106 stock options and 1,052,881 RSUs outstanding under the 2022 Plan
- The stock closed at $1.65 per share on May 18, 2026 (market cap ~$66M)
- Board unanimously recommends a FOR vote on all proposals including the equity plan amendment
- Other proposals: elect Class I directors and ratify appointment of PwC as auditor for FY2026
Financial Impact
Request to add 3,000,000 shares to the equity plan — at the $1.65 closing price, the total potential new issuance represents roughly $4.95M in notional value, or ~7.5% of current market cap; but shares are not issued immediately and will be granted over time under vesting schedules
Risk Factors
- If shareholders reject the plan, the company may need to shift to cash-based compensation, increasing cash burn rate
- Potential dilution from eventual issuance of 3M shares, though grants are typically staggered over years
- No disclosed financial results in this filing — limited fundamental read-through
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-236858 |
| Document: 0001193125-26-236858-index-headers.html | 0001193125-26-236858 |
| Document: 0001193125-26-236858-index.html | 0001193125-26-236858 |
| Document: 0001193125-26-236858.txt | 0001193125-26-236858 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 21, 2026 13w ago | Press Release | $1.68 $1.76 | ▲ +4.76% | ▲ +1.50% | $1.73 (+2.98%) |
May 22, 2026 22w ago | DEFA14A | $1.67 $2.39 | ▲ +43.11% | ▲ +40.39% | $1.73 (+3.59%) |
Apr 30, 2026 25w ago | DEFA14A | $1.85 $1.56 | ▼ −15.68% | ▼ −18.78% | $1.73 (−6.49%) |
Mar 19, 2026 31w ago | Press Release | $1.70 $1.52 | ▼ −10.59% | ▼ −24.93% | $1.73 (+1.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers